Employees: 635
Size Zota Health Care (ZOTA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $427M, the 917th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,314 on 18 Nov 2026.
Performance Over six months the shares gained 9.1%, against -25.4% for the median peer and +3.8% for the India market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 69.0% over the last twelve months (peer median +5.5%); the operating margin is -15.6% (peer median 2.6%).
Valuation It trades at 6.2× enterprise value to sales against a peer median of 2.9× (6th most expensive of 20).
Capital Return on invested capital runs 20.4 points below its cost of capital (10.7% WACC).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹6.79B | ₹5.39B | ₹2.92B | ₹1.80B | ₹1.39B |
| Revenue growth | — | +84% | +62% | +29% | — |
| Gross profit | ₹733M | ₹605M | ₹221M | ₹310M | ₹305M |
| EBITDA | -₹2.75M | ₹186M | -₹49.7M | ₹76.7M | ₹74.9M |
| Net income | -₹1.13B | -₹739M | -₹564M | -₹143M | -₹57.7M |
| Free cash flow | n/a | -₹2.05B | -₹949M | -₹218M | -₹137M |
| Capital expenditure | n/a | ₹1.26B | ₹460M | ₹167M | ₹125M |
| Total debt | ₹2.71B | ₹2.70B | ₹1.40B | ₹953M | ₹451M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ZOTA.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.3% | -13.0% | highest of 21 |
| 6-month return | +9.1% | -25.4% | 3rd highest of 21 |
| Distance from 52-week high | -24.4% | -46.9% | 3rd highest of 21 |
| Revenue growth (TTM) | +69.0% | +5.5% | 4th highest of 20 |
| Operating margin | -15.6% | 2.6% | 7th lowest of 20 |
| EV / Sales | 6.2× | 2.9× | 6th most expensive of 20 |
| ROIC minus cost of capital | -20.4 pp | -4.8 pp | 5th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zota Health Care ZOTA.NS | India | $427M | +9% | +69% | -16% | 6.2× | n/a | n/a |
| Ovid Therapeutics OVID | United States | $427M | -5% | -78% | -4,700% | 208.3× | n/a | n/a |
| Shanghai Shenqi Pharmaceutical Investment Management 600613.SS | China | $427M | +4% | -4% | 3% | 1.2× | 10.6% | +1.4% |
| Hyundai Bioscience 048410.KS | South Korea | $424M | -50% | +78% | -580% | 164.0× | n/a | n/a |
| Zhuhai Rundu Pharmaceutical 002923.SZ | China | $430M | -30% | +14% | 5% | 2.2× | 1.4% | -1.3% |
| Synmosa Biopharma 4114.TWO | Taiwan | $423M | -1% | +21% | 10% | 2.2× | 5.4% | +15.3% |
| Beijing Foyou Pharma 601089.SS | China | $423M | -27% | +5% | 10% | 0.2× | n/a | n/a |
| JW Pharmaceutical 001060.KS | South Korea | $423M | -26% | +9% | 13% | 0.7× | -15.4% | +7.2% |
| Phathom Pharmaceuticals PHAT | United States | $431M | -55% | +87% | -9% | 2.9× | n/a | n/a |
| Tevogen TVGN | United States | $422M | -38% | n/a | n/a | n/a | n/a | n/a |
| Shaanxi Kanghui Pharmaceutical Co 603139.SS | China | $421M | -31% | +1% | -39% | 7.1× | n/a | n/a |
| Cheng Du Sheng Nuo Biotec 688117.SS | China | $433M | -48% | +51% | 27% | 3.4× | -0.2% | +14.5% |
| Zhejiang Huakang Pharmaceutical 605077.SS | China | $433M | -47% | +35% | 4% | 1.1× | n/a | n/a |
| Kexing Biopharm 688136.SS | China | $433M | -42% | -14% | -12% | 2.9× | n/a | n/a |
| Teyi Pharmaceutical 002728.SZ | China | $419M | -12% | -7% | 7% | 3.2× | 24.4% | +8.0% |
| Jiangsu Sihuan Bioengineering 000518.SZ | China | $437M | -8% | -17% | -28% | 10.6× | n/a | n/a |
| PKU Healthcare 000788.SZ | China | $437M | -12% | -49% | 5% | 2.1× | -5.6% | -5.6% |
| Harbin Medisan Pharmaceutical 002900.SZ | China | $437M | -16% | -5% | -29% | 4.2× | n/a | n/a |
| Cachet Pharmaceutical 002462.SZ | China | $441M | -25% | -14% | 0% | 0.2× | -9.9% | -3.4% |
| Elixiron Immunotherapeutics (Cayman) 7871.TWO | Taiwan | $412M | +64% | +6,162% | -194% | 119.7× | n/a | n/a |
| RPG Life Sciences RPGLIFE.NS | India | $443M | +10% | +15% | 17% | 5.3× | n/a | n/a |